Shikari® Certolizumab Neutralizing Antibodies ELISA Kit

Certolizumab neutralizing antibodies (NAbs) are a subset of anti-drug antibodies (ADAs) that specifically inhibit the pharmacological activity of certolizumab, a pegylated monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α). These neutralizing antibodies block the drug’s ability to bind TNF-α by either preventing the drug from attaching to its target or interfering with downstream signaling. The development of NAbs can diminish certolizumab’s therapeutic efficacy and lead to disease flare-ups or treatment resistance, especially in autoimmune conditions like rheumatoid arthritis or Crohn’s disease.

Monitoring for certolizumab NAbs is clinically valuable, particularly in patients experiencing reduced response to therapy or adverse immunogenic reactions. Neutralizing antibody assays, such as competitive ligand-binding formats, are used to detect and quantify NAbs based on their ability to prevent certolizumab from binding its target. The presence of high NAb titers can guide therapeutic decisions, including dose adjustments, switching to alternative biologics, or evaluating compliance.

In research settings, quantifying certolizumab NAbs allows better understanding of immunogenicity profiles and supports biosimilar development by comparing immune responses. Moreover, NAb testing is often used alongside total ADA measurements to distinguish between non-neutralizing and neutralizing responses, improving pharmacovigilance and personalized treatment strategies in inflammatory disease management.

This product is manufactured in Turkey by Matriks Biotek.